molecular oncology tumor board in colorectal …...molecular oncology tumor board in colorectal...
TRANSCRIPT
Molecular oncology tumor board in colorectal cancer:Bench to bedside to bench - The virtuous cycle of research13-14 October 2017 - Genoa, Italy
PracTice Teaching course
FinaL PrograMMe
2 3
ge
ne
ra
L i
nF
o
generaL inForMaTion
4 5
Cme Provider EXCEMED is a non-profit foundation dedicated, since the last four decades, to the development of high-quality medical education programmes all over the world. EXCEMED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACCME®) which states that continuing medical education must be balanced, independent, objective and scientifically rigorous.
EXCEMED adheres to the principles of the Good CME Practice group (gCMEp).
OverviewSuccessful management of colorectal cancer should incorporate molecular testing and multimodal treatment. Insights into the biology of the disease and biomarker-driven therapeutic strategies are expected to improve survival and rationalise therapeutic approaches. Genome sequencing technologies are revealing many new genetic variants of high clinical relevance. To accelerate insights into the biology of the disease and the development of new treatments,interactions between researchers and clinicians should be a 'virtuous cycle' of bench to bedside and bench again.
Learning objectivesBy attending this practice teaching course, participants will be able to:•recapitulatecolorectalcancerbiologyandselectmoleculartestsofclinicalrelevance•evaluatebiomarker-drivenstrategiesandestablisha“continuumofcare”inpatientswith colorectal cancer•implementthedesignandinterpretationofclinicaltrialsincolorectalcancer
Target audiencePracticing clinicians who have an interest in understanding colorectal cancer biology and building individual competencies in the management of the disease.
Chairalberto sobreroDepartment of Medical OncologyIRCCS San Martino ISTGenoa, Italy
EXCEMED designed this programme in partnership with Prova Education.
Molecular oncology tumor board in colorectal cancer:Bench to bedside to bench - The virtuous cycle of research
An application has been made to the EACCME® for CME accreditation of the “Molecular oncology tumor board in colorectal cancer: Bench to bedside to bench – The virtuous cycle of research”tobeheldon13-14October2017inGenoa,Italyisdesignatedforamaximumof 8 (eight) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME® credits are recognized by the American Medical Association (AMA) towards the Physician’s Recognition Award (PRA). To convert EACCME®credittoAMAPRAcategory1credit,pleasecontacttheAMA.
Continuing medical educationEXCEMED (www.excemed.org) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net
6 7
VenueThis practice teaching course takes place at the:nh collection genova MarinaMolo Ponte Calvi, 5Genoa, Italy
LanguageThe official language of this practice teaching course is English.
CME ProviderEXCEMED - Excellence in Medical EducationProgramme Manager: Michela [email protected]
Medical Advisor: Cristina [email protected]
For any logistic inquiry, please contact:Meridiano Congress International Senior Event Manager: Concetta Di [email protected]
Follow us on
Aiming for excellenceOne of the factors we depend on for crafting high-quality learning experiences is our Learning Effectiveness Programme. Participants are asked to submit a Pre-event, Post-event and Follow-up survey which assess their learning trajectory, satisfaction with the scientific programme, sense of confidence in the subject matter and possible commitment to change in clinical practice. Participant feedback helps us enormously and we thank everyone in advance for their cooperation. Those who complete the surveys are eligible to receive their CME certificate after the event.
Our programme allows you to add your voice to the conversation Express your opinion, pose questions and engage with faculty. Our objective is to help you get the most from your learning experience with us. We wish you a unique learning experience.
Live graphic recordingSome lectures will also be supported by Live Graphic Recording, an innovative illustrated reportage technique featuring a live artist who chronicles the proceedings using keywords, images, charts and diagrams. Think of it as a visual summary to creatively and symbolically help participants retain key points.
8 FacuLTY
Fac
uLT
Y
10 11
rodrigo DienstmannOncology Data Science (ODysSey) GroupVall d'Hebron Institute of OncologyBarcelona (Spain)andComputational Oncology GroupSage BionetworksSeattle, USA
Paola gazzanigaCirculating Tumor Cells UnitDepartment of Molecular MedicineSapienza University of RomeRome, Italy
claus-henning KöhneDepartment of Oncology and HematologyKlinikum OldenburgOldenburg, Germany
Francesco saverio PapadiaDepartment of Surgical Sciences andIntegrated Diagnostics (DISC)School of Medical and Pharmaceutical SciencesUniversity of GenoaGenoa, Italy
alberto sobreroDepartment of Medical OncologyIRCCS San Martino ISTGenoa, Italy
Faculty
12 13PrograMMe
Pr
og
ra
MM
e
14 15
09.15 introduction A. Sobrero (Italy)
session i 09.30 L1: Management of advanced colorectal cancer A. Sobrero (Italy)
10.00 L2: Molecular determinants for first-line treatment in mcrc C.H. Köhne (Germany)
This lecture will be graphically recorded
10.30 L3: second-line treatment and beyond in mcrc A. Sobrero (Italy)
This lecture will be graphically recorded
11.00 coffee Break
11.15 Working groups clinical cases solving C.H. Köhne (Germany); F.S. Papadia (Italy); A. Sobrero (Italy)
12.45 Question time
13.00 Lunch
Friday, 13 october 2017
session ii
14.00 L4: Dominant molecular pathways in crc R. Dienstmann (Spain)
14.30 L5: Tumor heterogeneity P. Gazzaniga (Italy)
This lecture will be graphically recorded
15.00 L6: colorectal molecular subtypes and beyond R. Dienstmann (Spain)
15.30 coffee Break
15.45 L7: Tissue sampling bias and liquid biopsy P. Gazzaniga (Italy)
This lecture will be graphically recorded
16.15 Question time
16.30 PaTienT ManageMenT Molecular oncology & Medical oncology: interprofessional dialogues R. Dienstmann (Spain); P. Gazzaniga (Italy); C.H. Köhne (Germany); A. Sobrero (Italy)
17.15 end of the first day
Legend
L: Lecture : Working groups : Question time : Wrap-Up time : Graphic recording
16 17
session iii
09.15 Wrap-up time
09.30 L8: Three versus six months adjuvant chemotherapy in stage iii colon cancer A. Sobrero (Italy)
10.00 L9: To treat or not to treat stage ii crc C.H. Köhne (Germany)
10.30 coffee Break
10.45 Working groups clinical cases solving C.H. Köhne (Germany); F.S. Papadia (Italy); A. Sobrero (Italy)
11.15 L10: evolving clinical trial design in crc R. Dienstmann (Spain)
This lecture will be graphically recorded
11.45 L11: interpretation of clinical trials results A. Sobrero (Italy)
This lecture will be graphically recorded
12.15 cLinicaL TriaLs Molecular oncology & Medical oncology: interprofessional dialogues R. Dienstmann (Spain); P. Gazzaniga (Italy); C.H. Köhne (Germany); A. Sobrero (Italy)
This interprofessional dialogue will be graphically recorded
13.00 concluding remarks
end of the course
closing Lunch
saturday, 14 october 2017
EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:
rodrigo Dienstmann Declared receipts of grants and contracts from Merck; to be member of an advisory board, board of directors or other similar groups of Roche, Novartis and Symphogen.
Francesco saverio Papadia Declared no potential conflict of interest.
Paola gazzaniga Declared no potential conflict of interest.
The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off- label)usesofdrugsasof6October2017.
alberto sobrero claus-henning Köhne
Faculty disclosures
Legend
L: Lecture : Working groups : Question time : Wrap-Up time : Graphic recording
BiograPhies
Bio
gr
aP
hie
s
20 21
Paola gazzaniga
Circulating Tumor Cells UnitDepartment of Molecular MedicineSapienza University of RomeRome, Italy
Paola Gazzaniga currently holds the position of Professor of Molecular Oncology at Department of Molecular Medicine, Sapienza University of Rome. Her involvement in liquid biopsy research stems from her experience in molecular pathology and abilities in the molecular characterization of tumor cells. In the last 10 years she published more than20 papers on the molecular portrait ofCTCs, demonstrating the importance of epithelial-mesenchymal transition in CTCs. She also published for the first time about the use of CTCs as predictive biomarkers of response to cancer immunotherapy. She is involved in international working groups that are dealing with the demonstration of the clinical utility of liquid biopsy. Her research is currently focused to the non-invasive monitoring of colorectal cancer molecular evolution over the course of therapies through ctDNA analysis. She is highly committed to pursue the aim of achieving definitive level of evidence for the clinical applicability of liquid biopsies.
rodrigo Dienstmann
Oncology Data Science (ODysSey) GroupVall d'Hebron Institute of OncologyBarcelona (Spain)andComputational Oncology GroupSage Bionetworks Seattle, USA
Rodrigo Dienstmann is a medical oncologist with expertise in clinical and translational research. After graduating in Brazil, he moved to Spain for training in phase 1 developmentof cancer drugs. He helped develop a molecular prescreening strategy to match genomic profile of each patient’s tumor to targeted agents, the central dogma of precision oncology. During his post-graduation at the Massachusetts General Hospital Molecular Pathology Lab, he helped implement next-generation sequencing tests with standardized reports in the clinics, designed the framework for genomic variant annotation, prioritization and interpretation, together with a comprehensive gene-drug knowledge database of predictive genomic biomarkers in solid tumors. He then assisted the Sage Bionetworks Computational Oncology team in the development of novel predictive and prognostic models using cancer genomics data, focusing in colorectal
cancer subtping and gene expression sinatures for patient stratification. He is now Principal Investigator of the Oncology Data Science Group of Vall d’Hebron Institute of Oncology, coordinating clinical-molecular databases and integrating clinical and translational research with genomics and immunophenotyping of tumors for precision cancer therapy. He is also Head of the Molecular Prescreening Program, which guides patient recruitment in phase 1 trials withtargeted agents and immunotherapies at the institution.
22 23
Francesco saverio Papadia
Department of Surgical Sciences and Integrated Diagnostics (DISC) School of Medical and Pharmaceutical Sciences University of Genoa Genoa, Italy
Francesco Saverio Papadia was in Genoa, Italy and has attended the German School in Genoa (Deutsche Schule Genua). He graduated from University of GenoaSchoolofMedicine in1998,withan MD thesis entitled "Recent physiologic acquisitions and new strategies of use of biliopancreatic diversion in Obesity". He then enrolled in the General Surgery residency programme, University of GenoaSchoolofMedicinein1998,underthe supervision of Professor Nicola Scopinaro. During his training, he has focused primarily on digestive surgery, with special emphasis on surgical Oncology and Bariatric Surgery. He has been appointed as Assistant Professor of Surgery at University of Genoa School ofMedicine in2004,andhasbeenstaffsurgeon at the Surgical Department, University of Genoa School of Medicine, since July 2005. His research interestsfocus primarily on digestive surgery, both for malignant conditions as well as functional diseases. He has autored over
50publicationsinpeer-reviewedjournalsand surgical textbooks and been invited as faculty in international meetings; he also regularly mentors students, residents and fellows, together with being Fellow of the American College of Surgeons since 2016. He is happilymarried with a wonderful and quite patient wife, Francesca, who has three turbulent kids with, Anna, Pietro and Filippo.
claus-henning Köhne
Department of Oncology and HematologyKlinikum OldenburgOldenburg, Germany
Claus-Henning Köhne studied medicine at the Medical School Hannover in Germany and at the University of Glasgow in Scotland, specializing in internal medicine, haematology and oncology. He has since held senior positions at the Robert-Rössle-Hospital (Department of Haematology/Oncology and Tumour Immunology), Humboldt-University of Berlin (Charité), and at the University Hospital Rostock, Clinic and Policlinic of Internal Medicine, Department of Haematology/Oncology. Prior to his current positions he was appointed Professor of Medical Oncology at the Medical Clinic I, University Carl-Gustav-Carus of the Technical University Dresden. He is a member of the European Society for Medical Oncology (ESMO) and currently chairs the Oncology Pro advisory group of ESMO, the American Society of Clinical Oncology (ASCO) and the Gastrointestinal Tract Cancer Cooperative Group of the EORTC (GITCCG), where he has served as
secretary. He is also a member of the AIO Germany and the German Cancer Society. He serves as a consultant for the European Agency for Medicinal Products (EMA) and coordinated several EORTC-trials as well as being a Founding Member of the Pan-European Trials for ad-juvant colon Cancer (PETACC). Prof. Köhne is a special guest professor of the First Affiliated Hospital of Dalian Medical University/China and a visiting Professor of Dalian Medical University of the Second Affiliated Hospital/China, where he is also a member of the Sino-German-Cancer-Center Oldenburg/Dalian. He also organizes the ESMO Preceptorship programme for colorectal cancer. Prof. Köhne is a reviewer of various journals including the International Journal of Cancer, Oncology, Annals of Oncology (for which he is also a board member), Critical Reviews in Oncology/Haematology, Onkologie, British Journal of Cancer and Journal of Clinical Oncology.
24 25
alberto sobrero
Department of Medical Oncology IRCCS San Martino IST Genoa, Italy
Alberto Sobrero is the Head of the Medical Oncology Unit at Ospedale San Martino in Genova, Italy. After his MD from the University of Genova, he took up the position of postdoctoral Associate in Medical Oncology at Yale University, Connecticut. After receiving his medical degree from the University of Genova, Prof. Sobrero took up the position of postdoctoral Associate in Medical Oncology at Yale University, USA. In 1983, he became AssociateResearch Scientist in Medical Oncology at Yale. Before returning to Genova in 1985, he completed a residency inInternal Medicine at the Yale Affiliated Norwalk Hospital.From2002 to2006,ProfessorSobrerohas been the Chairman of the Protocol Review Committee of the EORTC and has been part of the faculty of the ASCO-FECS Clinical Research courses at Flims for 7 years. He has servedon the editorial board of the Journal of Clinical Oncology 2004-2006, hasbeen part of the Scientific Committee
of ASCO (2007-2008), the EducationalCommittee of ESMO (2008-2014,Chair of the GI committee 2012-2016)and is the chairman of the ESMO President Nominating Committee. He has received theESMOaward in 2016and is the chairman of the scientific committeeoftheESMO2017congress.His main research interests include gastrointestinal cancer treatment and design and interpretation of clinical trials in oncology.
Learning oBjecTives
Lear
nin
g oB
jecT
ives
28 29
Molecular determinants for first-line treatment in mcrcC.H. Köhne (Germany)L2
Management of advanced colorectal cancerA. Sobrero (Italy)L1
NOTES NOTES
Learning objectives:•Review the clinical (primary tumor location) and molecular determinants (RAS-WT andRAS-Mutateddisease)for1sttimetreatment
•Criticallyanalyseresultsfrominternationaltrials(FIRE3andCALGB/SWOG80405)•Explain current options for oligometastatic disease
Learning objectives:•Illustrate clinical and molecular heterogeneity of CRC•Describe the rapidly evolving treatment scenario in CRC•Summarizekeyadvancesin2017
30 31
Dominant molecular pathways in crcR. Dienstmann (Spain)L4
second-line treatment and beyond in mcrcA. Sobrero (Italy)L3
NOTES NOTES
Learning objectives:•Classify critical driver genomics event in CRC•Define tumor microenvironment (stromal and immune components) and its role in CRC•Describe convergent pathway dependencies
Learning objectives:•Describetreatmentgoalsandtreatmentoptionsin2ndlineandbeyond•Illustrate how to best integrate new treatment options •Define treatment re-introduction and re-challenge strategies
32 33
Tumor heterogeneityP. Gazzaniga (Italy)L5
NOTES
Learning objectives:•Explain the complex nature of cancer and the concept of tumor heterogeneity •Analyse clonal evolution of CRC and response to therapy•Formulate translational implications of tumor heterogeneity
colorectal molecular subtypes and beyondR. Dienstmann (Spain)L6
NOTES
Learning objectives:•Illustrate consensus CMS•Discuss clinical relevance of CMS•Describe cancer-cell intrinsic gene expression
34 35
Three versus six months adjuvant chemotherapy in stage iii colon cancerA. Sobrero (Italy)L8
Tissue sampling bias and liquid biopsyP. Gazzaniga (Italy)L7
NOTES NOTES
Learning objectives:•Reviewandinterpretresultsfrommatureclinicaltrials(ESMO2017)•Define high-risk patients and low-risk patients
Learning objectives:•Combine tumor heterogeneity and tissue sampling bias •Describe longitudinal sampling strategies liquid biopsy•Explain the clinical relevance of longitudinal monitoring of mCRC
36 37
evolving clinical trial design in crcR. Dienstmann (Spain)L10
To treat or not to treat stage ii crcC.H. Köhne (Germany)L9
NOTES NOTES
Learning objectives:•Describe the validation process for predictive biomarkers •Critically analyse patients stratification and endpoint definition •Review advances in clinical trials designed in the era of personalized medicine
Learning objectives:•Summarize risk factors and outcome of stage II CRC•Define molecular determinants for adjuvant therapy•Illustrate gene signatures in CRC
38 39
interpretation of clinical trials resultsA. Sobrero (Italy)L11
NOTES
Learning objectives:•Discriminate clinically relevant results from clinical trials•Distinguish“bigdata”from“smartdata”•Review examples from most recent trials in CRC (Success/Failure)
NOTES
40 41
NOTESNOTES
42 43
NOTESNOTES
44 45
NOTESNOTES
46 47
NOTESNOTES
48
All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED. This programme is made possible thanks to an educational grant received from Merck KGaA, Darmstadt, Germany and San Raffaele Hospital, Milan, Italy.
50
eXceMeD - excellence in Medical education 14,RueduRhône,1204Geneva,Switzerland
Improving the patient’s life through medical education
www.excemed.org
Copyright © eXCemeD, 2017. All rights reserved.